RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 93.5%

Neg 0% Neu 0% Pos 93.5%

RBC Capital analyst Brian Abrahams upgrades Lakefront Biotherapeutics (NASDAQ:LKFT) from Sector Perform to Outperform and raises the price target from $26 to $45.